摘要
目的探讨利脑心片联合替格瑞洛治疗不稳定心绞痛的临床疗效。方法选取2021年3月—2023年2月在北京市大兴区人民医院治疗的不稳定心绞痛患者96例,采用随机数字表法将患者分为对照组(48例)和治疗组(48例)。对照组患者口服替格瑞洛片,首次负荷剂量180 mg,之后剂量改为90 mg/次,2次/d。治疗组患者在对照组基础上口服利脑心片,3片/次,3次/d。两组患者治疗6个月。观察两组患者临床疗效,比较治疗前后两组患者血小板反应指数(PRI)、腺苷二磷酸诱导的血小板-纤维蛋白凝块强度(MAADP)及血清C反应蛋白(CRP)、单核细胞趋化蛋白-1(MCP-1)和基质金属蛋白酶-9(MMP-9)水平。结果治疗后,治疗组总有效率为93.75%,明显高于对照组79.17%(P<0.05)。治疗后,两组PRI、MAADP、CRP、MCP-1、MMP-9水平均低于治疗前(P<0.05),且治疗组明显低于对照组(P<0.05)。结论利脑心片联合替格瑞洛治疗不稳定心绞痛安全有效,可有效降低血栓形成风险,且不增加出血风险,改善体内炎症反应。
Objective To explore the clinical efficacy of Linaoxin Tablets combined with ticagrelor in treatment of unstable angina pectoris.Methods A total of 96 patients with unstable angina pectoris treated in Daxing District People's Hospital of Beijing from March 2021 to February 2023 were selected and divided into control group(48 cases)and treatment group(48 cases)by random number table method.Patients in the control group were po administered with Ticagrelor Tablets,the initial loading dose was 180 mg,and then the dose was changed to 90 mg/time,twice daily.Patients in the treatment group were po administered with Linaoxin Tablets on the basis of the control group,3 tablets/time,three times daily.Patients in two groups were treated for 6 months.After treatment,the clinical evaluations were evaluated,the levels of PRI,MAADP,CRP,MCP-1,and MMP-9 in two groups before and after treatment were compared.Results After treatment,the clinical effective rate of the treatment group was 93.75%,which was significantly higher than that of the control group(79.17%,P<0.05).After treatment,the levels of PRI,MAADP,CRP,MCP-1,and MMP-9 in two groups were lower than those before treatment(P<0.05),and these indexes levels in the treatment group were significantly lower than the control group(P<0.05).Conclusion Linaoxin Tablets combined with ticagrelor is safe and effective in treatment of unstable angina pectoris,can effectively reduce the risk of thrombosis without increasing the risk of bleeding and improve the inflammatory response in the body.
作者
任爽
刘懿颖
李洋
巴晓彤
REN Shuang;LIU Yiying;LI Yang;BA Xiaotong(Department of Emergency,Beijing Daxing District People’s Hospital,Beijing 102600,China;Department of Cardiology,Beijing Daxing District People’s Hospital,Beijing 102600,China)
出处
《现代药物与临床》
CAS
2024年第3期647-651,共5页
Drugs & Clinic
基金
首都卫生发展科研专项项目(2020-4-7082)。